Zhao Tingting, Wang Dalong, Zhao Shan, Chen Jing, Dou Tongyi, Ge Guangbo, Wang Changyuan, Meng Qiang, Sun Huijun, Liu Kexin, Wu Jingjing
College of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian, 116023, China.
Curr Drug Metab. 2021;22(5):391-398. doi: 10.2174/1389200222666210210115509.
Both clotrimazole and ketoconazole have been verified to have an inhibitory effect on CYP3A4. hCE2 is an enzyme closely related to the side effects of several anti-cancer drugs. However, the interactions between hCE2, clotrimazole, and ketoconazole remain unclear.
The objective of this study was to investigate and compare the inhibition behaviors of the two antifungal agents, ketoconazole and clotrimazole, on the human liver microsome hCE2 and to explore their underlying mechanism.
The inhibitory effects were investigated in human liver microsomes (HLMs) using fluorescein diacetate (FD), N-(2-butyl-1,3-dioxo-2,3-dihydro-1H-phenalen-6-yl)-2-chloroacetamide (NCEN) and irinotecan (CPT- 11) as substrates of hCE2.
Clotrimazole significantly inhibited the hCE2 activity, which was manifested by attenuated fluorescence when the substrates were FD and NCEN. The inhibitory effect of clotrimazole towards hCE2 was much stronger than that of ketoconazole, and the inhibitory behaviors displayed substrate-dependent inhibition. The IC value of clotrimazole, with CPT-11 as the substate, increased by 5 and 37 times more than that with FD and NCEN, respectively. Furthermore, the inhibitions of clotrimazole towards hCE2-mediated hydrolysis of FD, NCEN, and CPT-11 were all in competitive mode with the Ki values of 0.483 μM, 8.63 μM, and 29.0 μM, respectively. Molecular docking result of clotrimazole binding to hCE2 illustrated that clotrimazole could efficiently orient itself in the Z site cavity of hCE2.
Clotrimazole displayed a strong inhibitory effect against hCE2, which might be used as a potential combined agent co-administrated with CPT-11 to alleviate the hCE2-mediated severe side effects.
克霉唑和酮康唑均已被证实对CYP3A4有抑制作用。人羧酸酯酶2(hCE2)是一种与多种抗癌药物副作用密切相关的酶。然而,hCE2、克霉唑和酮康唑之间的相互作用仍不清楚。
本研究旨在研究和比较两种抗真菌药物酮康唑和克霉唑对人肝微粒体hCE2的抑制行为,并探讨其潜在机制。
使用二醋酸荧光素(FD)、N-(2-丁基-1,3-二氧代-2,3-二氢-1H-菲-6-基)-2-氯乙酰胺(NCEN)和伊立替康(CPT-11)作为hCE2的底物,在人肝微粒体(HLMs)中研究抑制作用。
克霉唑显著抑制hCE2活性,当底物为FD和NCEN时,表现为荧光减弱。克霉唑对hCE2的抑制作用比酮康唑强得多,且抑制行为表现为底物依赖性抑制。以CPT-11为底物时,克霉唑的半数抑制浓度(IC)值分别比以FD和NCEN为底物时增加了5倍和37倍。此外,克霉唑对hCE2介导的FD、NCEN和CPT-11水解的抑制均为竞争性模式,其抑制常数(Ki)值分别为0.483 μM、8.63 μM和29.0 μM。克霉唑与hCE2结合的分子对接结果表明,克霉唑能够在hCE2的Z位点腔中有效定位。
克霉唑对hCE2显示出强烈的抑制作用,可作为与CPT-11联合使用的潜在药物,以减轻hCE2介导的严重副作用。